The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.
The company said it plans to use the net proceeds for working capital and general corporate purposes.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.
The company will use the net proceeds to finance its current operations and expand its US commercialization capacities for its lead product, Epi proColon.
The company said it will use the proceeds from the offering for working capital and general corporate purposes, among other things.
The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.
The company said it would use the proceeds of the offering to promote its genetic tests and services, among other things.
The company announced this week the sale of 9,090,909 shares of common stock, which it expects will raise proceeds of roughly $30 million before expenses.
The company is offering approximately 8.8 million shares of common stock at a price of $171 per share.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.